Association Between Pathologic Response and Survival Following Neoadjuvant Targeted Therapy in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma

表皮生长因子受体 腺癌 比例危险模型 肿瘤科 新辅助治疗 分级(工程) 危险系数 医学 肺癌 内科学 生存分析 靶向治疗 生物 癌症 生态学 置信区间 乳腺癌
作者
Chenyang Dai,Xiaodong Yang,Delun Yang,Zhao An,Huikang Xie,Shengnan Zhao,Chunyan Wu,Deping Zhao,Chang Chen
出处
期刊:European Journal of Cardio-Thoracic Surgery [Oxford University Press]
卷期号:67 (8) 被引量:3
标识
DOI:10.1093/ejcts/ezaf269
摘要

OBJECTIVES: The International Association for the Study of Lung Cancer (IASLC) recommended applying a 10% residual viable tumour (%RVT) threshold for major pathological response (MPR) to all therapies. However, evidence supporting the association between pathological regression and prognosis after neoadjuvant targeted therapy is lacking. METHODS: This study retrospectively included 228 patients with epidermal growth factor receptor-mutant adenocarcinoma receiving neoadjuvant targeted therapy. The optimal %RVT cutoff for predicting recurrence-free survival (RFS) was determined using maximally selected rank statistics and Youden's index. RFS was evaluated utilizing Kaplan-Meier methods and Cox proportional hazard analyses. RESULTS: The median %RVT was 50%, with 17% of patients achieving MPR. Patients with %RVT ≤ 10% (MPR) had a significantly better RFS than those with %RVT > 10% (non-MPR) (P = .012). Moreover, the optimal %RVT cutoff for RFS was 75%. Multivariable analysis revealed that %RVT > 75% was an independent risk factor for RFS (P = .045). When stratified by 10% and 75% RVT, patients with %RVT > 75% had the worst RFS, followed by those with %RVT 10%-75%, while patients with %RVT ≤10% had the best survival (P = .0023). The IASLC adenocarcinoma grading system retained prognostic significance after targeted therapy (P < .0001) and was confirmed as an independent prognostic factor (P = .006). It also exhibited synergistic prognostic value with a 10% RVT (P < .0001). CONCLUSIONS: This study verified the association between tumour regression and prognosis after neoadjuvant targeted therapy. A 10% RVT threshold stratified the prognosis, validating the IASLC's MPR for use in neoadjuvant targeted therapy, while a 75% RVT cutoff also proved useful for prognostic discrimination. These findings require validation by prospective studies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
难过丹寒发布了新的文献求助10
1秒前
1秒前
RZY完成签到,获得积分10
1秒前
科目三的应助被iidodo采纳,获得10
2秒前
Shuang完成签到,获得积分10
3秒前
3秒前
喷火娃的应助被瓜兮兮CYY采纳,获得10
3秒前
4秒前
4秒前
5秒前
斯文败类的应助被皆辰采纳,获得10
5秒前
6秒前
6秒前
8秒前
脑洞疼的应助被许伟洋采纳,获得10
9秒前
SmileLin发布了新的文献求助10
9秒前
zzz完成签到,获得积分10
9秒前
难过丹寒发布了新的文献求助10
9秒前
传奇3的应助被Pululuu采纳,获得10
10秒前
11秒前
11秒前
XLL完成签到,获得积分10
11秒前
PLANB完成签到 ,获得积分10
12秒前
O基米德发布了新的文献求助10
13秒前
與世無爭发布了新的文献求助10
13秒前
14秒前
水合钴离子完成签到 ,获得积分10
14秒前
14秒前
MADAO发布了新的文献求助30
15秒前
xxxxxxzz完成签到,获得积分20
15秒前
xoy完成签到 ,获得积分10
15秒前
实验小学五道杠大队长完成签到,获得积分10
16秒前
细心又菡的应助被kskfjs采纳,获得20
17秒前
li完成签到,获得积分10
17秒前
hele发布了新的文献求助10
18秒前
頔頔哒哒发布了新的文献求助10
19秒前
聪慧的寄凡完成签到 ,获得积分10
19秒前
21秒前
顾矜的应助被等风归采纳,获得10
21秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181888
求助须知:如何正确求助?哪些是违规求助? 9571628
关于积分的说明 21818887
捐赠科研通 7778145
什么是DOI,文献DOI怎么找? 3433528
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621